Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research lowered shares of Trevi Therapeutics (NASDAQ:TRVI) from a hold rating to a sell rating in a research note published on Thursday morning, Zacks.com reports.

According to Zacks, “Trevi Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in patients with Parkinson’s disease. Trevi Therapeutics Inc. is based in New Haven, Connecticut. “

A number of other analysts also recently issued reports on TRVI. Svb Leerink began coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an outperform rating and a $14.00 price objective for the company. Leerink Swann began coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an outperform rating for the company. Stifel Nicolaus began coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued a buy rating and a $20.00 price objective for the company. Needham & Company LLC began coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued a buy rating and a $18.00 price objective for the company. Finally, BMO Capital Markets began coverage on shares of Trevi Therapeutics in a report on Monday, June 3rd. They issued an outperform rating and a $15.00 price objective for the company. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Trevi Therapeutics currently has a consensus rating of Buy and a consensus price target of $16.75.

NASDAQ TRVI opened at $4.65 on Thursday. Trevi Therapeutics has a 12-month low of $4.04 and a 12-month high of $10.62. The firm has a 50-day simple moving average of $4.87.

Institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth approximately $26,000. Morgan Stanley bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth approximately $42,000. Northern Trust Corp bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth approximately $124,000. Vanguard Group Inc. bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth approximately $886,000. Finally, Omega Fund Management LLC bought a new stake in shares of Trevi Therapeutics during the 2nd quarter worth approximately $9,476,000. 79.48% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease.

Featured Story: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Trevi Therapeutics (TRVI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Trevi Therapeutics (NASDAQ:TRVI)

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.